Condition
Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
100%
3 of 3 completed with results
Key Signals
3 with results100% success
Data Visualizations
Phase Distribution
3Total
P 2 (1)
P 3 (2)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT01419717Phase 3CompletedPrimary
Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
NCT00950911Phase 3CompletedPrimary
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
NCT00104650Phase 2CompletedPrimary
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
Showing all 3 trials